Exact Mass: 344.2674936
Exact Mass Matches: 344.2674936
Found 464 metabolites which its exact mass value is equals to given mass value 344.2674936,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Medroxyprogesterone
Medroxyprogesterone, or MP is a progestin (synthetic progestogen). MP is not used medically, as it is over two orders of magnitude less potent than medroxyprogesterone acetate (MPA); a derivative of MP (PMID: 16784762). MP may be formed via the metabolism of MPA. Medroxyprogesterone acetate is used to treat conditions such as absent or irregular menstrual periods, or abnormal uterine bleeding. Synthetic progestogens are widely used to simulate the effects of progesterone; a natural female sex hormone. Progesterone is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss (PMID: 20104424). In addition to progestagenic activity, MP is also a weak antiandrogen in vitro (PMID: 29990947). Medroxyprogesterone is only found in individuals that have used or taken MPA. A synthetic progesterone (steroid hormone) involved in the female menstrual cycle, pregnancy (supports gestation) and embryogenesis of humans and other species. Progesterone belongs to a class of hormones called progestagens, and is the major naturally occurring human progestagen. -- Wikipedia G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03A - Hormonal contraceptives for systemic use > G03AC - Progestogens G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03D - Progestogens > G03DA - Pregnen (4) derivatives L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02A - Hormones and related agents > L02AB - Progestogens C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents
Testosterone Propionate
Testosterone Propionate is only found in individuals that have used or taken this drug. It is an ester of testosterone with a propionate substitution at the 17-beta position. [PubChem]The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects. C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
Medrysone
Medrysone is only found in individuals that have used or taken this drug. It is a corticosteroid used in ophthalmology. [Wikipedia]There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Initially, the drug binds to the glucocorticoid receptor in the cytosol. This migrates to the nucleus and binds to genetic elements which cause activation and repression of the involved genes in the inflammatory pathway. D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D005938 - Glucocorticoids S - Sensory organs > S01 - Ophthalmologicals > S01B - Antiinflammatory agents > S01BA - Corticosteroids, plain C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid Same as: D02289
Lamtidine
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist
16-Propyl-3-methoxy-estra-1,3,5(10)-triene-16beta,17beta-diol
17-hydroxy-17-methylandrosta-4,6-dien-3-yl acetate
(4Z,7Z,10Z,13Z,16Z,19Z)-22-Hydroxydocosahexaenoic acid
A HDoHE obtained by hydroxylation at position 2 of all-cis-docosa-4,7,10,13,16,19-hexaenoic acid.
Methenolone Acetate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid
16b-Hydroxystanozolol
C21H32N2O2 (344.24636519999996)
16b-Hydroxystanozolol is the major metabolite of stanozolol. Stanozolol is an anabolic steroid illicitly used for growth promoting purposes in animal production. For reasons of public health the use of anabolic steroids as growth promoters is officially banned in Europe in animals intended for consumption. Stanozolol is an anabolic steroid banned in competing athletes. Doping control screening for the analysis of anabolic steroids in human urine or the detection of anabolic steroid residues in cattles urine is achieved using liquid and gas chromatography time-of-flight mass spectrometry, liquid chromatography-tandem mass spectrometry or through a combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry. Androgenic anabolic steroids are defined as natural, synthetic or semi-synthetic drugs chemicals derived from testosterone, used with the aim to improve physical performance by increasing both muscle strength and mass. Despite their reported toxicological effects on the cardiovascular, hepatic and neuro-endocrine systems, the AAS have been extensively used in sports activities. (PMID: 15782394, 17610244, 17724580) [HMDB] 16b-Hydroxystanozolol is the major metabolite of stanozolol. Stanozolol is an anabolic steroid illicitly used for growth promoting purposes in animal production. For reasons of public health the use of anabolic steroids as growth promoters is officially banned in Europe in animals intended for consumption. Stanozolol is an anabolic steroid banned in competing athletes. Doping control screening for the analysis of anabolic steroids in human urine or the detection of anabolic steroid residues in cattles urine is achieved using liquid and gas chromatography time-of-flight mass spectrometry, liquid chromatography-tandem mass spectrometry or through a combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry. Androgenic anabolic steroids are defined as natural, synthetic or semi-synthetic drugs chemicals derived from testosterone, used with the aim to improve physical performance by increasing both muscle strength and mass. Despite their reported toxicological effects on the cardiovascular, hepatic and neuro-endocrine systems, the AAS have been extensively used in sports activities. (PMID: 15782394, 17610244, 17724580).
3'-Hydroxystanozolol
C21H32N2O2 (344.24636519999996)
3-Hydroxystanozolol is a metabolite of stanozolol. Stanozolol has the potential for misuse as an anabolic steroid in horse racing. Stanozolol is an anabolic steroid illicitly used for growth promoting purposes in animal production. For reasons of public health the use of anabolic steroids as growth promoters is officially banned in Europe in animals intended for consumption. Stanozolol is a synthetic anabolic androgenic steroid often abused in sports to enhance performance. Doping control screening for the analysis of anabolic steroids in human urine or the detection of anabolic steroid residues in cattles urine is achieved using liquid and gas chromatography time-of-flight mass spectrometry, liquid chromatography-tandem mass spectrometry or through a combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry. Androgenic anabolic steroids are defined as natural, synthetic or semi-synthetic drugs chemicals derived from testosterone, used with the aim to improve physical performance by increasing both muscle strength and mass. Despite their reported toxicological effects on the cardiovascular, hepatic and neuro-endocrine systems, the AAS have been extensively used in sports activities. [HMDB] 3-Hydroxystanozolol is a metabolite of stanozolol. Stanozolol has the potential for misuse as an anabolic steroid in horse racing. Stanozolol is an anabolic steroid illicitly used for growth promoting purposes in animal production. For reasons of public health the use of anabolic steroids as growth promoters is officially banned in Europe in animals intended for consumption. Stanozolol is a synthetic anabolic androgenic steroid often abused in sports to enhance performance. Doping control screening for the analysis of anabolic steroids in human urine or the detection of anabolic steroid residues in cattles urine is achieved using liquid and gas chromatography time-of-flight mass spectrometry, liquid chromatography-tandem mass spectrometry or through a combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry. Androgenic anabolic steroids are defined as natural, synthetic or semi-synthetic drugs chemicals derived from testosterone, used with the aim to improve physical performance by increasing both muscle strength and mass. Despite their reported toxicological effects on the cardiovascular, hepatic and neuro-endocrine systems, the AAS have been extensively used in sports activities.
17-HDoHE
Docosahexaenoic acid (DHA) is a omega-3 essential fatty acid that reduces the incidence and severity of a number of diseases. Recently, a novel series of DHA-derived lipid mediators with potent protective actions has been identified. In this study we demonstrate that dietary amplification of these DHA-derived products protects the liver from necroinflammatory injury. In vitro, supplementation of hepatocytes with DHA significantly reduced hydrogen peroxide-induced DNA damage, evaluated by the "comet assay," and oxidative stress, determined by measurement of malondialdehyde levels. In vivo, dietary supplementation of mice with DHA ameliorated carbon tetrachloride-induced necroinflammatory damage. In addition, hepatic cyclooxygenase-2 expression and PGE2 levels were significantly reduced in mice fed DHA-enriched diets. In these animals, increased hepatic formation of DHA-derived lipid mediators (i.e., 17S-hydroxy-DHA (17S-HDHA) and protectin D1) was detected by HPLC-gas chromatography/mass spectrometry analysis. Consistent with these findings, synthetic 17-HDHA abrogated genotoxic and oxidative damage in hepatocytes and decreased TNF-alpha release and 5-lipoxygenase expression in macrophages. In a transactivation assay, 17-HDHA acted in a concentration-dependent manner as a PPARgamma agonist. Taken together, these findings identify a potential role for DHA-derived products, specifically 17S-HDHA and protectin D1, in mediating the protective effects of dietary DHA in necroinflammatory liver injury. (PMID: 17056761). This fatty acyl belongs to the main class of docosanoids. (Lipid Maps). Docosahexaenoic acid (DHA) is a omega-3 essential fatty acid that reduces the incidence and severity of a number of diseases. Recently, a novel series of DHA-derived lipid mediators with potent protective actions has been identified. In this study we demonstrate that dietary amplification of these DHA-derived products protects the liver from necroinflammatory injury. In vitro, supplementation of hepatocytes with DHA significantly reduced hydrogen peroxide-induced DNA damage, evaluated by the "comet assay," and oxidative stress, determined by measurement of malondialdehyde levels. In vivo, dietary supplementation of mice with DHA ameliorated carbon tetrachloride-induced necroinflammatory damage. In addition, hepatic cyclooxygenase-2 expression and PGE2 levels were significantly reduced in mice fed DHA-enriched diets. In these animals, increased hepatic formation of DHA-derived lipid mediators (i.e., 17S-hydroxy-DHA (17S-HDHA) and protectin D1) was detected by HPLC-gas chromatography/mass spectrometry analysis. Consistent with these findings, synthetic 17-HDHA abrogated genotoxic and oxidative damage in hepatocytes and decreased TNF-alpha release and 5-lipoxygenase expression in macrophages. In a transactivation assay, 17-HDHA acted in a concentration-dependent manner as a PPARgamma agonist. Taken together, these findings identify a potential role for DHA-derived products, specifically 17S-HDHA and protectin D1, in mediating the protective effects of dietary DHA in necroinflammatory liver injury. (PMID: 17056761)
20-HDoHE
20-HDoHE is an autoxidation product of docosahexaenoic acid DHA. 20-HDoHE is a long-chain polyunsaturated fatty acid that is any docosahexaenoic acid bearing a single hydroxy substituent. An oxidation product of docosahexaenoic acid metabolism. (CHEBI:72790)
4-HDoHE
4-HDoHE is an endogenous oxidized unsaturated fatty acids. Human and mouse plasma samples also catalyzed 4-HDoHE lactonization and 5-HETE lactone hydrolysis. (PMID: 12963475) 4-HDoHE is a hydroxydocosahexaenoic acid that consists of 5E,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid bearing an additional 4-hydroxy substituent. (CHEBI:72624)
7-HDoHE
7-HDoHE is an autoxidation product of docosahexaenoic acid DHA. 7-HDoHE is a long-chain polyunsaturated fatty acid that is any docosahexaenoic acid bearing a single hydroxy substituent. An oxidation product of docosahexaenoic acid metabolism. (CHEBI:72790)
Dodecanoylcarnitine
C19H37NO4 (344.28006880000004)
Dodecanoylcarnitine is an acylcarnitine. More specifically, it is an dodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular Dodecanoylcarnitine is elevated in the blood or plasma of individuals with very long chain acyl-CoA dehydrogenase deficiency (PMID: 9034211), Yin deficiency (PMID: 31909891), multiple acyl coenzyme A dehydrogenase deficiency (PMID: 30510944), CVD in type 2 diabetes Mellitus (PMID: 32431666), and diastolic heart failure (PMID: 26010610). It is also decreased in the blood or plasma of individuals with Celiac disease (PMID: 16425363), psoriasis (PMID: 28695330), intracerebral hemorrhage (PMID: 29265114), and pregnancy (PMID: 24704061 - in serum of pregnant women with fetus with CHD). Dodecanoylcarnitine is elevated in the urine of individuals with renal cell carcinoma (PMID: 29658093). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). Dodecanoylcarnitine is also present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I deficiency, and carnitine palmitoyltransferase II deficiency (PMID: 12828998 ). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. Dodecanoylcarnitine is an acylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I deficiency, and carnitine palmitoyltransferase II deficiency. (PMID 12828998) [HMDB]
8-HDoHE
8-HDoHE is an autoxidation product of docosahexaenoic acid DHA. 8-HDoHE is a long-chain polyunsaturated fatty acid that is any docosahexaenoic acid bearing a single hydroxy substituent. An oxidation product of docosahexaenoic acid metabolism. (CHEBI:72790)
16-HDoHE
16-HDoHE is an autoxidation product of docosahexaenoic acid DHA. 16-HDoHE is a long-chain polyunsaturated fatty acid that is any docosahexaenoic acid bearing a single hydroxy substituent. An oxidation product of docosahexaenoic acid metabolism. (CHEBI:72790)
11-HDoHE
11-HDoHE is an autoxidation product of docosahexaenoic acid DHA. 11-HDoHE is a long-chain polyunsaturated fatty acid that is any docosahexaenoic acid bearing a single hydroxy substituent. An oxidation product of docosahexaenoic acid metabolism. (CHEBI:72790)
10-HDoHE
10-HDoHE is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. (±)10-HDoHE is a potential marker of oxidative stress in brain and retina where DHA is an abundant polyunsaturated fatty acid. (http://bioreagent.bertinpharma.com)
3-Hydroxyneogrifolin
3-Hydroxyneogrifolin is found in mushrooms. 3-Hydroxyneogrifolin is a constituent of Albatrellus ovinus. Constituent of Albatrellus ovinus. 3-Hydroxyneogrifolin is found in mushrooms.
MG(17:0/0:0/0:0)
MG(17:0/0:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(17:0/0:0/0:0) is made up of one heptadecanoyl(R1).
Anacardic acid
Anacardic acid is found in cashew nut. Anacardic acid is found in cashew nut shell.Anacardic acids are chemical compounds found in the shell of the cashew nut (Anacardium occidentale). Chemically, anacardic acid is a mixture of several closely related organic compounds. Each consists of a salicylic acid substituted with an alkyl chain that has 15 or 17 carbon atoms; anacardic acid is a mixture of saturated and unsaturated molecules. The exact mixture depends on the species of the plant and the major component is C5:3 all-Z. (Wikipedia Found in cashew nut shell
19(20)-EpDPE
19(20)-EpDPE is a DHA epoxygenase metabolite, derived via epoxidation of the w-3 double bond of DHA. The EDHF (endothelium-derived hyperpolarizing factor) activity of 19(20)-EpDPE has not yet been determined. The epoxygenase metabolites of DHA have also been detected in a murine inflammation model (PMID: 12391014). EDHF is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators (PMID: 9504399, 10519554). Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as 14(15)-EpETrE which are prime candidates for the actual active mediator (PMID: 9401962). However, the CYP450 metabolites of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been little studied relative to arachidonate epoxygenase metabolites. 19(20)-EpDPE is a DHA epoxygenase metabolite, derived via epoxidation of the w-3 double bond of DHA. The EDHF activity of 19(20)-EpDPE has not yet been determined. The epoxygenase metabolites of DHA have also been detected in a murine inflammation model
DG(8:0/8:0/0:0)
Diglycerides (DGs) are also known as diacylglycerols or diacylglycerides, meaning that they are glycerides consisting of two fatty acid chains covalently bonded to a glycerol molecule through ester linkages. DG(8:0/8:0/0:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of caprylic acid at the C-2 position. Mono- and diacylglycerols are common food additives used to blend together certain ingredients, such as oil and water, which would not otherwise blend well. Diacylglycerols are often found in bakery products, beverages, ice cream, chewing gum, shortening, whipped toppings, margarine, and confections. C78276 - Agent Affecting Digestive System or Metabolism
16(17)-EpDPE
16(17)-EpETE is the DHA homolog of 14(15)-EpETrE, derived via epoxidation of the 16,17-double bond of docosahexaenoic acid (DHA). The EDHF (endothelium-derived hyperpolarizing factor) activity of 16(17)-EpDPE has not yet been determined. The epoxygenase metabolites of DHA have also been detected in a murine inflammation model (PMID: 12391014). EDHF is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators (PMID: 9504399, 10519554). Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as 14(15)-EpETrE which are prime candidates for the actual active mediator (PMID: 9401962). However, the CYP450 metabolites of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been little studied relative to arachidonate epoxygenase metabolites. EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators.1,2 Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as 14(15)-EpETrE which are prime candidates for the actual active mediator.3 However, the CYP450 metabolites of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been little studied relative to arachidonate epoxygenase metabolites. 16(17)-EpETE is the DHA homolog of 14(15)-EpETrE, derived via epoxidation of the 16,17-double bond of docosahexaenoic acid (DHA). The EDHF activity of 16(17)-EpDPE has not yet been determined. The epoxygenase metabolites of DHA have also been detected in a murine inflammation model [HMDB]
MG(i-17:0/0:0/0:0)
MG(i-17:0/0:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(i-17:0/0:0/0:0) is made up of one 15-methylhexadecanoyl(R1).
4b-Hydroxystanozolol
C21H32N2O2 (344.24636519999996)
4b-Hydroxystanozolol is a metabolite of stanozolol. Stanozolol has the potential for misuse as an anabolic steroid in horse racing. Stanozolol is an anabolic steroid illicitly used for growth promoting purposes in animal production. For reasons of public health the use of anabolic steroids as growth promoters is officially banned in Europe in animals intended for consumption. Stanozolol is a synthetic anabolic androgenic steroid often abused in sports to enhance performance. Doping control screening for the analysis of anabolic steroids in human urine or the detection of anabolic steroid residues in cattles urine is achieved using liquid and gas chromatography time-of-flight mass spectrometry, liquid chromatography-tandem mass spectrometry or through a combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry. (PMID: 16040239, 17724580, 17610244, 15782394).
10,20-Dihydroxyeicosanoic acid
10,20-Dihydroxyeicosanoic acid is found in fruits. 10,20-Dihydroxyeicosanoic acid is isolated from the leaf cutin of Limonia acidissima (wood apple Isolated from the leaf cutin of Limonia acidissima (wood apple). 10,20-Dihydroxyeicosanoic acid is found in fruits.
1-Phenyl-1,3-heptadecanedione
1-Phenyl-1,3-heptadecanedione is found in fats and oils. 1-Phenyl-1,3-heptadecanedione is a constituent of the pollen of Helianthus annuus (sunflower) Constituent of the pollen of Helianthus annuus (sunflower). 1-Phenyl-1,3-heptadecanedione is found in fats and oils.
4-Hydroxy-all-trans-retinyl acetate
This compound belongs to the family of Retinoids. These are compounds that is related to vitamin A, especially retinol.
MG(0:0/a-17:0/0:0)[rac]
MG(0:0/a-17:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(0:0/a-17:0/0:0) is made up of one 14-methylhexadecanoyl(R2).
MG(a-17:0/0:0/0:0)[rac]
MG(a-17:0/0:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(a-17:0/0:0/0:0) is made up of one 14-methylhexadecanoyl(R1).
MG(0:0/i-17:0/0:0)
MG(0:0/i-17:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(0:0/i-17:0/0:0) is made up of one 15-methylhexadecanoyl(R2).
MG(0:0/17:0/0:0)
MG(0:0/17:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(0:0/17:0/0:0) is made up of one heptadecanoyl(R2).
DG(8:0/0:0/8:0)
DG(8:0/0:0/8:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
1,2-Dioctanoylglycerol
C78276 - Agent Affecting Digestive System or Metabolism
Becocalcidiol
(5-Methyl-2-propan-2-ylcyclohexyl) 2-[4-(2-methylpropyl)phenyl]propanoate
Bempedoic acid
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C80482 - Non-Statin Antilipidemic Agent C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents D009676 - Noxae > D000963 - Antimetabolites D007004 - Hypoglycemic Agents D004791 - Enzyme Inhibitors Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor[1]. Bempedoic acid (ETC-1002) activates AMPK[2].
methoxyprogesterone
(8R,9S,10R,13S,14S,16R,17S)-16-Ethyl-17-(2-hydroxyacetyl)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
18,19-O-Isopropylidene-18,19-dihydroxyisopimara-8(14),15-diene
18,19-Dinorcholesta-1,3,5,7,9,11,13-heptaene,17-methyl-, (17a)- (9CI)
(1R*,3E,7E,9S*,11S*)-9-acetoxydolabella-3,7,12-trien-16-al
2-(4,8-dimethylnona-3,7-dienyl)-3,4-dihydro-2,7-dimethyl-2H-[1]benzopyran-3,5-diol
3beta-acetoxy-8,11,13-abietatrien-12-ol|3beta-acetoxyabieta-8,11,13-trien-12-ol
19-Acetoxy-12,17-epoxy-14alpha-methyl-15-nor-pimara-12,16-dien|19-acetoxy-12,17-epoxy-14alpha-methyl-15-nor-pimara-12,16-diene
(5alpha,14alpha,17beta)-pregn-20-en-3beta-ol-3-acetate|3beta-acetoxy-5alpha-pregn-20-ene|3beta-hydroxy-pregna-20-en-3-acetate|5alpha-Pregn-20-en-3beta-yl-acetat
12-O-acetyl-18-hydroxyferruginol|O-Acetyl-18-hydroxyferruginol
bacchalineol acetate|bacchalineol-18-acetate|Hardwickiolacetat
(9E)-8,11,12-trihydroxyoctadecenoic acid methyl ester|tianshic acid methyl ester
5-methyl-2-[(2E,7Z)-3,7,11-trimethyl-2,7-dodecadien-9-onyl]-1,4-dihydroxybenzene
18-Acetoxy-3,13(16),14-clerodatrien-2-one|2-oxo-18-acetoxy-10alpha,17alpha,19alpha,20beta-(-)-cleroda-3,13(16),14-triene
5-methyl-2-[(2E,6E)-3,7,11-trimethyl-2,6-dodecadien-9-onyl]-1,4-dihydroxybenzene
6-alpha-acetoxyvouacapane|6alpha-Acetoxyvouacapane
5-Cholen-3beta-ol|Chal-5-en-3beta-ol|Chol-5-en-3beta-ol
(+)-(2S)-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadecan-4-one|(+)-(S)-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadecan-4-one|(+)-(S)-protomethine|(+)-protomethine
C20H32N4O (344.25759819999996)
7(R*)-acetoxy-13-keto-(1S*,11R*)-dolabella-3(E),8(17),12(18)-triene|Ac-7-Hydroxy-3,8(17),12(18)-dolabellatrien-13-one
(4S*,14S*)-4-acetoxy-14-hydroxydolasta-1(15),7,9-triene|4(SR)-acetoxy-14(SR)-hydroxydolast-1(15),7,9-triene
3(R)-acetoxy-1(S),11(R),12(S)-dolabell-4(E),8(E),18-trien-16-al
(-)-(4S,5S,10R,20R)-12,18-dihydroxyabieta-8,11,13-trien-20-aldehyde 18,20-ethyl acetal
An abietane diterpenoid isolated from the stem bark of Fraxinus sieboldiana.
3beta-3-Hydroxy-24-nor-5-cholen-23-al|3beta-hydroxy-23,24-bisnorchol-5-en-22-carbaldehyde|3beta-hydroxy-24-norchol-5-en-23-al
2-methyl-2-((3E)-4,8-dimethylnona-37-dienyl)-3,4-dihydro-2H-1-benzopyran-8-methoxy-6-ol
(1R,3E,7E,11S,12S)-17-acetoxy-14-oxo-3,7,18-dolabellatriene
(1R,3E,6R,7E,11S,12S)-6-acetoxy-14-oxo-3,7,18-dolabellatriene
Sporidesmolinsaeure B|Sporidesmolsaeure|Sporidesmolsaeure B|Sporidesmolsaeure, L-alpha-Hydroxy-isovaleryl-L-valyl-N-methyl-L-leucin
C17H32N2O5 (344.23111020000005)
(1R,3E,5R,7E,11S,12S)-5-acetoxy-14-oxo-3,7,18-dolabellatriene
17-oxo-3,4-seco-9betaH?17-octanorlanost-4(28),7-dien-3-oic acid|seco-coccinic acid H
3,7,11,15-tetramethyl-15-hexadecene-1,2,3,14-tetraol
(1R,3E,7S,11S,12S)-7-acetoxy-14-oxo-3,8(17),18-dolabellatriene
(Z,Z)-4-(8,11-Heptadecadienyl)-1,2-benzenediol|(Z,Z)-4-(heptadeca-8,11-dienyl)benzene-1,2-diol|4-(8,11-Heptadecadienyl)-1,2-benzenediol|4-<8Z,11Z-heptadecadienyl>catechol
3alpha,4alpha-epoxy-5alpha-acetoxysphenoloba-13Z,16E,18-triene
15,16-epoxy-ent-labda-8(17),13(16),14-trien-19-ol acetate
Me ether-(9beta,10alpha,16alpha)-16-Hydroxypregn-4-ene-3,20-dione
7beta-hydroxy-12-acetoxyabieta-8,11,13-triene|fortunin A
Me ester-(17alphaOH)-17-Hydroxypregn-4-ene-3,20-dione
15-ethoxy-8,11,13-abietatriene-18-oic acid|8,11,13-abietatriene-15-ethoxy-18-oic acid|abiesadine P
17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid
20-HDoHE
A hydroxydocosahexaenoic acid that consists of 4Z,7Z,10Z,13Z,16Z,18E-docosahexaenoic acid bearing an additional 20-hydroxy substituent.
4-HDoHE
A hydroxydocosahexaenoic acid that consists of 5E,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid bearing an additional 4-hydroxy substituent.
(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
MLS001076155-01!6ALPHA-METHYL-11BETA-HYDROXYPROGESTERONE
Medroxyprogesterone - CASMI2016 Category 1 - Challenge 13
2-hydroxy-3-methyl-6-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]-7-oxabicyclo[4.1.0]hept-3-en-5-one
medroxyprogesterone
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03A - Hormonal contraceptives for systemic use > G03AC - Progestogens G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03D - Progestogens > G03DA - Pregnen (4) derivatives L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02A - Hormones and related agents > L02AB - Progestogens C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents CONFIDENCE standard compound; INTERNAL_ID 8739
ST 22:3;O3
CONFIDENCE standard compound; INTERNAL_ID 1391; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10301; ORIGINAL_PRECURSOR_SCAN_NO 10299 C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones CONFIDENCE standard compound; INTERNAL_ID 1391; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10334; ORIGINAL_PRECURSOR_SCAN_NO 10329 CONFIDENCE standard compound; INTERNAL_ID 1391; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10348; ORIGINAL_PRECURSOR_SCAN_NO 10343 CONFIDENCE standard compound; INTERNAL_ID 1391; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10391; ORIGINAL_PRECURSOR_SCAN_NO 10386 CONFIDENCE standard compound; INTERNAL_ID 1391; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10401; ORIGINAL_PRECURSOR_SCAN_NO 10399 CONFIDENCE standard compound; INTERNAL_ID 1391; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10415; ORIGINAL_PRECURSOR_SCAN_NO 10413 G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03A - Hormonal contraceptives for systemic use > G03AC - Progestogens G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03D - Progestogens > G03DA - Pregnen (4) derivatives L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02A - Hormones and related agents > L02AB - Progestogens D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents CONFIDENCE standard compound; INTERNAL_ID 2395 INTERNAL_ID 2395; CONFIDENCE standard compound
8-HDoHE
A hydroxydocosahexaenoic acid that consists of 4Z,6E,10Z,13Z,16Z,19Z-docosahexaenoic acid bearing an additional 8-hydroxy substituent. CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0120.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0120.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0120.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001273.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001273.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001273.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001273.mzML; PROCESSING averaging of repeated ion fragments at 40.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001273.mzML; PROCESSING averaging of repeated ion fragments at 30.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001273.mzML; PROCESSING averaging of repeated ion fragments at 20.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ]
16-HDoHE
A hydroxydocosahexaenoic acid that consists of 4Z,7Z,10Z,13Z,17E,19Z-docosahexaenoic acid bearing an additional 16-hydroxy substituent. CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0112.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ]; CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0112.mzML CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0112.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0112.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001271.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001271.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001271.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001271.mzML; PROCESSING averaging of repeated ion fragments at 40.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001271.mzML; PROCESSING averaging of repeated ion fragments at 30.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001271.mzML; PROCESSING averaging of repeated ion fragments at 20.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ]
11-HDoHE
A hydroxydocosahexaenoic acid that consists of 4Z,7Z,9E,13Z,16Z,19Z-docosahexaenoic acid with the hydroxy group located at position 11. CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0079.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0079.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0079.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001275.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001275.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001275.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001275.mzML; PROCESSING averaging of repeated ion fragments at 40.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001275.mzML; PROCESSING averaging of repeated ion fragments at 30.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001275.mzML; PROCESSING averaging of repeated ion fragments at 20.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ]
10-HDoHE
A hydroxydocosahexaenoic acid that consists of 4Z,7Z,11E,13Z,16Z,19Z-docosahexaenoic acid bearing an additional 10-hydroxy substituent. CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0239.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0239.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0239.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001269.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001269.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001269.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001269.mzML; PROCESSING averaging of repeated ion fragments at 40.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001269.mzML; PROCESSING averaging of repeated ion fragments at 30.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001269.mzML; PROCESSING averaging of repeated ion fragments at 20.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ]
2-hydroxy-3-methyl-6-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]-7-oxabicyclo[4.1.0]hept-3-en-5-one [IIN-based: Match]
UNII:SA9937IP23
1,2-diacyl-sn-glycerol in which both the 1- and 2-acyl groups are specified as octanoyl. Formula C19H36O5.
(5Z,7E)-(1S,3R)-1,3-dihydroxy-9,10-seco-23,24-dinor-5,7,10(19)-cholatrien-22-one
(5Z,7E)-(1S,3R)-24-nor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
(5Z,7E)-(3S,22S)- 24-nor-9,10-seco-5,7,10(19)-cholatriene-3,22-diol
(5E,7E)-(3S,22R)- 24-nor-9,10-seco-5,7,10(19)-cholatriene-3,22-diol
(5Z,7E)-(3S)-24-nor-9,10-seco-5,7,10(19)-cholatriene-3,23-diol
1α-Hydroxy-2-methylene-19-nor-(20S)-bishomopregnacalciferol
17(R)-HDoHE
A polyunsaturated fatty acid that is (4Z,7Z,10Z,13Z,15E,19Z)-docosa-4,7,10,13,15,19-hexaenoic acid carrying a hydroxy substituent at the 17R-position.
17(S)-HDoHE
A polyunsaturated fatty acid that is (4Z,7Z,10Z,13Z,15E,19Z)-docosa-4,7,10,13,15,19-hexaenoic acid carrying a hydroxy substituent at the 17S-position. It is a metabolite of docosahexaenoic acid in human blood and mouse brain, and serves as a precursor to 17(S)-resolvins.
Phytophthora mating hormone alpha1
Plastoquinol-1
7Z,10Z,13Z,15E,19Z-17-keto-docosapentaenoic acid
Methyl α-Linolenyl Fluorophosphonate
Methyl γ-Linolenyl Fluorophosphonate
3-Hydroxyneogrifolin
FA 18:2;O4
ascr#19
An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,11R)-11-hydroxydodec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.
oscr#19
An omega-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E)-12-hydroxydodec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.
1alpha-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3
1alpha-hydroxy-24,25,26,27-tetranorvitamin D3
(5Z,7E)-(3S,22R)- 24-nor-9,10-seco-5,7,10(19)-cholatriene-3,22-diol
(22S)-22-hydroxy-24,25,26,27-tetranorvitamin D3
(5E,7E)-(3S,22S)- 24-nor-9,10-seco-5,7,10(19)-cholatriene-3,22-diol
1alpha-Hydroxy-2-methylene-19-nor-(20S)-bishomopregnacalciferol
5-((8Z,11Z)-heptadeca-8,11-dien-1-yl)resorcinol
2-hydroxy-6-[(8Z,11Z)-pentadeca-8,11-dienyl]benzoic acid
tert-butyl 9-benzyl-2,9-diazaspiro[5.5]undecane-2-carboxylate
C21H32N2O2 (344.24636519999996)
2,2-dimethyl-1-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1,8-naphthyridin-1-yl]propan-1-one
CIS-7,10,13,16,19-DOCOSAPENTAENOIC ACID METHYL ESTER
3-Methoxy-18-methylestra-2,5(10)dien-17-one 17-ethylene ketal
Tert-Butyl 9-benzyl-3,9-diazaspiro[5.5]undecane-3-carboxylate
C21H32N2O2 (344.24636519999996)
Acetic acid,2-mercapto-, octadecyl ester
C20H40O2S (344.27488600000004)
Pregn-5-en-20-one,16,17-epoxy-3-hydroxy-16-methyl-, (3b,16a)-
3-(4,4-DIETHOXY-BUTYLAMINO)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
3-ETHOXY-6-METHYL-3,5-ANDROSTADIENE-11-BETA-OL-17-ONE
1-boc-4-[(2-cyano-ethyl)-pyridin-3-ylmethyl-amino]-piperidine
tert-butyl 8-benzyl-2,8-diazaspiro[4.5]decane-2-carboxylate
C21H32N2O2 (344.24636519999996)
4-tert-butylphenol,formaldehyde,4-(2-methylbutan-2-yl)phenol
1-(4-methyl-1-piperazinyl)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-Ethanone
(5alpha,17beta)-Spiro[androstane-3,3-[3H]diazirin]-17-ol 17-acetate
C21H32N2O2 (344.24636519999996)
9,12-Octadecadien-1-ol, methanesulfonate, (9Z,12Z)-
C19H36O3S (344.23850260000006)
1,9-Diazaspiro[5.5]undecane-9-carboxylic acid, 1-(phenylmethyl)-, 1,1-dimethylethyl ester
C21H32N2O2 (344.24636519999996)
2,9-Diazaspiro[5.5]undecane-9-carboxylic acid, 2-(phenylmethyl)-, 1,1-dimethylethyl ester
C21H32N2O2 (344.24636519999996)
Becocalcidiol
D018977 - Micronutrients > D014815 - Vitamins > D004100 - Dihydroxycholecalciferols D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
1,3-Dioctanoylglycerol
A 1,3-diglyceride in which both acyl groups are specified as octanoyl.
2-hydroxyethyl 12-hydroxyoctadecanoate
D013501 - Surface-Active Agents > D011092 - Polyethylene Glycols D001697 - Biomedical and Dental Materials
(2E,11R)-11-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]dodec-2-enoic acid
(2E)-12-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]dodec-2-enoic acid
17beta-Hydroxy-5alpha-androst-1-en-3-one propionate
3beta-(Acetyloxy)-5alpha-androst-16-ene-16-carboxaldehyde
1,11,16-Trihydroxy-3,7,11,15-tetramethylhexadecan-4-one
(4Z,7Z,10Z,13Z,16Z)-18-[(2R,3S)-3-ethyloxiran-2-yl]octadeca-4,7,10,13,16-pentaenoic acid
N-(4-Carbamimidoylbenzyl)-1-(4-Methylpentanoyl)-L-Prolinamide
(4s,5e,7z,10z,13z,16z,19z)-4-Hydroxydocosa-5,7,10,13,16,19-Hexaenoic Acid
Medrysone
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D005938 - Glucocorticoids S - Sensory organs > S01 - Ophthalmologicals > S01B - Antiinflammatory agents > S01BA - Corticosteroids, plain C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid Same as: D02289
Bempedoic acid
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C80482 - Non-Statin Antilipidemic Agent C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents D009676 - Noxae > D000963 - Antimetabolites D007004 - Hypoglycemic Agents D004791 - Enzyme Inhibitors Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor[1]. Bempedoic acid (ETC-1002) activates AMPK[2].
(5Z,7E)-(3S,22R)-24-nor-9,10-seco-5,7,10(19)-cholatriene-3,22-diol
(5Z,7E)-(3S,22S)-24-nor-9,10-seco-5,7,10(19)-cholatriene-3,22-diol
(5E,7E)-(3S,22R)-24-nor-9,10-seco-5,7,10(19)-cholatriene-3,22-diol
MG(0:0/17:0/0:0)
MG(0:0/17:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(0:0/17:0/0:0) is made up of one heptadecanoyl(R2).
[(10R,13S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] propanoate
16 alpha-Ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione
(13E,15E,17E,19E)-20-(oxiren-2-yl)icosa-13,15,17,19-tetraenoic acid
5-[(2E)-2-(1-butan-2-yl-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene)ethylidene]-2-methylidenecyclohexane-1,3-diol
[3-Carboxy-2-(8-methylundecanoyloxy)propyl]-trimethylazanium
C19H38NO4+ (344.28006880000004)
[3-Carboxy-2-(7-methylundecanoyloxy)propyl]-trimethylazanium
C19H38NO4+ (344.28006880000004)
[3-Carboxy-2-(6-methylundecanoyloxy)propyl]-trimethylazanium
C19H38NO4+ (344.28006880000004)
[3-Carboxy-2-(4-methylundecanoyloxy)propyl]-trimethylazanium
C19H38NO4+ (344.28006880000004)
[3-Carboxy-2-(5-methylundecanoyloxy)propyl]-trimethylazanium
C19H38NO4+ (344.28006880000004)
[3-Carboxy-2-(10-methylundecanoyloxy)propyl]-trimethylazanium
C19H38NO4+ (344.28006880000004)
[3-Carboxy-2-(9-methylundecanoyloxy)propyl]-trimethylazanium
C19H38NO4+ (344.28006880000004)
[3-Carboxy-2-(3-methylundecanoyloxy)propyl]-trimethylazanium
C19H38NO4+ (344.28006880000004)
[3-carboxy-2-[(E)-2-hydroxyundec-3-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-2-hydroxyundec-8-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-2-hydroxyundec-6-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-2-hydroxyundec-5-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-2-hydroxyundec-4-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-2-hydroxyundec-7-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(Z)-2-hydroxyundec-2-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-2-hydroxyundec-9-enoyl]oxypropyl]-trimethylazanium
[3-Carboxy-2-(3-oxoundecanoyloxy)propyl]-trimethylazanium
Strongylin A
A sesquiterpenoid that is 1,2,3,4,4a,5,6,7,7a,8-decahydrobenzo[d]xanthene substituted by a hydroxy group at position 12, methyl groups at positions 4, 4, 7 and 7a and a methoxy group at position 9 (the 4aS,7S,7aR,13aS stereoisomer). Isolated from Strongylophora hartmani, it exhibits activity against the influenza virus.
(7Z,10Z,13Z,15E,19Z)-17-Oxodocosapentaenoic acid
A docosanoid that is (7Z,10Z,13Z,15E,19Z)-docosapentaenoic acid carrying an oxo substituent at position 17. An intermediate of specialised proresolving mediators.
(7Z,10Z,14E,16Z,19Z)-13-Oxodocosapentaenoic acid
An docosanoid that is (7Z,10Z,14E,16Z,19Z)-docosapentaenoic acid carrying an oxo substituent at position 13. An intermediate of specialised proresolving mediators.
Tianshic acid methyl ester
A fatty acid methyl ester of tianshic acid. It has been isolated from the stems of Sambucus williamsii.
5-Hydroxy-4-methyl-1-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]-7-oxabicyclo[4.1.0]hept-3-en-2-one
19(20)-Epoxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid
(7Z,10Z,12E,14E)-15-{(2S,3S)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-7,10,12,14-tetraenoic acid
1-[(6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)methoxy]-3-(1-methyl-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazin-2-yl)-2-propanol
C21H32N2O2 (344.24636519999996)
3-Carboxy-2-(dodecanoyloxy)-N,N,N-trimethylpropan-1-aminium
C19H38NO4+ (344.28006880000004)
Diethyl (3-ethyl-1-ethoxy-2-oxoheptyl)propanedioate
2-(dimethylamino)-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[oxo-(propan-2-ylamino)methyl]amino]ethyl]-3-oxanyl]acetamide
C16H32N4O4 (344.24234320000005)
17-Methylandrosta-4,6-diene-3beta,17beta-diol 3-acetate
(3R)-3,20-dihydroxyicosanoic acid
A dihydroxy monocarboxylic acid that is 20-hydroxyicosanoic acid in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group.
11alpha-Hydroxy-12alpha-methyl-pregn-4-ene-3,20-dione
(3R,19R)-19-dihydroxyicosanoic acid
An (omega-1)-hydroxy fatty acid that is (19R)-19-hydroxyicosanoic acid in which the 3-pro-R hydrogen is replaced by a hydroxy group.
(4Z,7S,8E,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoic acid
16-hydroxy-4(Z),7(Z),10(Z),13(Z),17(E),19(Z)-docosahexaenoic acid
(4Z,7Z,10Z,13Z,15E,19E)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid
(1-Hydroxy-3-propanoyloxypropan-2-yl) tridecanoate
Testosterone propionate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
17R-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid
(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosahexaenoic acid
A hydroxydocosahexaenoic acid that consists of 4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid bearing an additional 17-hydroxy substituent.
(4Z,7Z,10Z,13Z,19Z)-16,17-epoxydocosapentaenoic acid
An EpDPE obtained by formal epoxidation of the 16,17-double bond of docosa-4,7,10,13,16,19-hexaenoic acid.
(4Z,7Z,10Z,13Z,16Z)-19,20-epoxydocosapentaenoic acid
An EpDPE obtained by formal epoxidation of the 19,20-double bond of docosa-4,7,10,13,16,19-hexaenoic acid.
(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosahexaenoic acid
A hydroxydocosahexaenoic acid that consists of (4Z,7Z,10Z,14E,16Z,19Z)-docosahexaenoic acid bearing an additional 13-hydroxy substituent.
(+/-)-7-hydroxy-4Z,8E,10Z,13Z,16Z,19Z-docosahexaenoic acid
14-HDoHE
A hydroxydocosahexaenoic acid that consists of (4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoic acid bearing an additional 14-hydroxy substituent.
(4Z,7Z,13Z,16Z,19Z)-10,11-epoxydocosapentaenoic acid
An EpDPE obtained by formal epoxidation across the 10,11-double bond of all-cis-docosa-4,7,10,13,16,19-hexaenoic acid.
(4Z,7Z,10Z,16Z,19Z)-13,14-epoxydocosapentaenoic acid
An EpDPE obtained by formal epoxidation across the 13,14-double bond of all-cis-docosa-4,7,10,13,16,19-hexaenoic acid.
21-hydroxy-4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid
(8E,10Z,13Z,16Z,19Z)-7-oxodocosapentaenoic acid
A docosanoid that consists of (8E,10Z,13Z,16Z,19Z)-docosapentaenoic acid carrying an oxo substituent at position 7. An intermediate of specialised proresolving mediators.
(4Z,7Z,10Z,13Z,16Z,19S,20R)-19,20-epoxydocosapentaenoic acid
A (4Z,7Z,10Z,13Z,16Z)-19,20-epoxydocosapentaenoic acid with (19S,20R)-configuration.
(E)-8-(5-(1,4-dihydroxyhex-2-en-1-yl)-3-hydroxytetrahydrofuran-2-yl)octanoic acid
(E)-12-(5-ethyl-4-hydroxytetrahydrofuran-2-yl)-9,12-dihydroxydodec-10-enoic acid
(E)-9-hydroxy-11-(3-hydroxy-5-(1-hydroxypropyl)tetrahydrofuran-2-yl)undec-10-enoic acid
(E)-9-hydroxy-9-(4-hydroxy-5-(3-hydroxypent-1-en-1-yl)tetrahydrofuran-2-yl)nonanoic acid
(3R,7R,11R,15R)-1,11,16-trihydroxy-3,7,11,15-tetramethylhexadecan-4-one
(7Z,9E,11E,16Z,19Z)-13,14-epoxydocosapentaenoic acid
An epoxydocosapentaenoic acid (7Z,9E,11E,16Z,19Z)-docosapentaenoic acid in which the epoxy group is located at the 13,14-position. An intermediate in the specialised proresolving mediators
(4Z,7Z,10Z,13Z,16Z,19R,20S)-19,20-epoxydocosapentaenoic acid
A (4Z,7Z,10Z,13Z,16Z)-19,20-epoxydocosapentaenoic acid with (19R,20S)-configuration.
HDoHE
A long-chain polyunsaturated fatty acid that is any docosahexaenoic acid bearing a single hydroxy substituent. An oxidation product of docosahexaenoic acid metabolism.
dioctanoylglycerol
A diglyceride obtained by acylation of any two hydroxy groups of glycerol by octanoic acid. Formula C19H36O5. For the structure shown, either R1 = H and R2 = octanoyl or R1 = octanoyl and R2 = H.
7-Deacetoxyyanuthone A
A class I yanuthone that is 5,6-epoxy-4-hydroxy-3-methylcyclohex-2-en-1-one which is substituted at position 6 by an (E,E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl group (the R,R,R stereoisomer).
(16S,17S)-epoxy-(7Z,10Z,12E,14E,19Z)-docosapentaenoic acid
A (4Z,7Z,10Z,13Z,19Z)-16,17-epoxydocosapentaenoic acid in which the chiral centres at positions 16 and 17 both have S-configuration. An intermediate of specialized proresolving mediators
(4Z,8E,10Z,13Z,16Z,19Z)-7-hydroxydocosahexaenoic acid
A hydroxydocosahexaenoic acid that consists of (4Z,8E,10Z,13Z,16Z,19Z)-docosahexaenoic acid bearing an additional 7-hydroxy substituent.
21-HDoHE
A (omega-1)-hydroxy fatty acid that is (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid substituted at position 21 by a hydroxy group.
2,3-dioctanoyl-sn-glycerol
A 2,3-diacyl-sn-glycerol in which both the 2- and 3-acyl groups are specified as octanoyl.